



## Company Announcement

### **Nykode Therapeutics – resignation of Chair of the Board, Board Members, Chief Executive Officer, Chief Scientific Officer and Chief Financial Officer**

Oslo, Norway, March 27, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has received notices of termination from Martin Nicklasson, Chair of the Board of Directors and Elaine Sullivan and Anne Whitaker, members of the Board of Directors.

Further, Nykode has received notices of termination from Michael Engsig, Chief Executive Officer, Agnete Fredriksen, Chief Scientific Officer & Co-founder and Harald Gurvin, Chief Financial Officer. They will continue to support the company until further notice.

The Board will as soon as possible call for an Extraordinary General Meeting to elect a new Board.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Harald Gurvin, CFO at Nykode Therapeutics ASA, on March 27, 2025 at 13:33 CET.

#### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in 2 trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.



### **Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

### **Contact for Nykode Therapeutics ASA:**

Michael Engsig, Chief Executive Officer  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

### **Nykode Therapeutics ASA**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway